US 12,077,535 B2
Derivatives of resiquimod
Lihu Yang, Edison, NJ (US)
Assigned to SUPERB WISDOM LIMITED, Apia (WS)
Filed by Superb Wisdom Limited, Apia (WS)
Filed on Feb. 4, 2022, as Appl. No. 17/665,104.
Application 17/665,104 is a continuation of application No. 16/612,216, granted, now 11,274,099, previously published as PCT/US2018/033493, filed on May 18, 2018.
Claims priority of provisional application 62/508,722, filed on May 19, 2017.
Prior Publication US 2023/0002370 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 45/06 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 45/06 (2013.01); C07B 2200/05 (2013.01)] 22 Claims
 
1. A pharmaceutical composition comprising a compound having structural formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
each of R1, R2 and R3 is independently selected from CH3 and CD3;
each of Y1a, Y1b, Y2a, Y2b, Y3a, Y3b, Y4a, Y4b, Y4c, and Y4d is independently selected from hydrogen and deuterium;
each position that is designated as containing deuterium has at least 50.1% deuterium incorporation at that position and at least R1 or both R2 and R3 are CD3, and
Y1a and Y1b are the same;
Y2a and Y2b are the same;
Y3a and Y3b are the same; and
Y4a, Y4b, Y4c, and Y4d are the same.